iRhythm Technologies Inc

NASDAQ IRTC

Download Data

iRhythm Technologies Inc Market Capitalization on May 17, 2024: USD 2.95 B

iRhythm Technologies Inc Market Capitalization is USD 2.95 B on May 17, 2024, a -25.45% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.
  • iRhythm Technologies Inc 52-week high Market Capitalization is USD 3.97 B on May 22, 2023, which is 34.66% above the current Market Capitalization.
  • iRhythm Technologies Inc 52-week low Market Capitalization is USD 2.22 B on November 10, 2023, which is -24.74% below the current Market Capitalization.
  • iRhythm Technologies Inc average Market Capitalization for the last 52 weeks is USD 3.14 B.
NASDAQ: IRTC

iRhythm Technologies Inc

CEO Mr. Quentin S. Blackford
IPO Date Oct. 20, 2016
Location United States
Headquarters 699 8th Street, San Francisco, CA, United States, 94103
Employees 2,000
Sector Healthcare
Industry Medical devices
Description

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Similar companies

SRDX

SurModics Inc

USD 34.62

1.58%

OFIX

Orthofix Medical Inc

USD 15.00

-0.73%

StockViz Staff

May 20, 2024

Any question? Send us an email